Literature DB >> 7474076

Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.

L M Mylin1, R H Bonneau, J D Lippolis, S S Tevethia.   

Abstract

Simian virus 40 large tumor (T) antigen contains three H-2Db-restricted (I, II/III, and V) and one H-2Kb-restricted (IV) cytotoxic T lymphocyte (CTL) epitopes. We demonstrate that a hierarchy exists among these CTL epitopes, since vigorous CTL responses against epitopes I, II/III, and IV are detected following immunization of H-2b mice with syngeneic, T-antigen-expressing cells. By contrast, a weak CTL response against the H-2Db-restricted epitope V was detected only following immunization of H-2b mice with epitope loss variant B6/K-3,1,4 cells, which have lost expression of CTL epitopes I, II/III, and IV. Limiting-dilution analysis confirmed that the lack of epitope V-specific CTL activity in bulk culture splenocytes correlated with inefficient expansion and priming of epitope V-specific CTL precursors in vivo. We examined whether defined genetic alterations of T antigen might improve processing and presentation of epitope V to the epitope V-specific CTL clone Y-5 in vitro and/or overcome the recessive nature of epitope V in vivo. Deletion of the H-2Db-restricted epitopes I and II/III from T antigen did not increase target cell lysis by epitope V-specific CTL clones in vitro. The amino acid sequence SMIKNLEYM, which species an optimized H-2Db binding motif and was found to induce CTL in H-2b mice, did not further reduce epitope V presentation in vitro when inserted within T antigen. Epitope V-containing T-antigen derivatives which retained epitopes I and II/III or epitope IV did not induce epitope V-specific CTL in vivo: T-antigen derivatives in which epitope V replaced epitope I failed to induce epitope V-specific CTL. Recognition of epitope V-H-2Db complexes by multiple independently derived epitope V-specific CTL clones was rapidly and dramatically reduced by incubation of target cells in the presence of brefeldin A compared with the recognition of the other T-antigen CTL epitopes by epitope specific CTL, suggesting that the epitope V-H-2Db complexes either are labile or are present at the cell surface at reduced levels. Our results suggest that processing and presentation of epitope V is not dramatically altered (reduced) by the presence of immunodominant CTL epitopes in T antigen and that the immunorecessive nature of epitope V is not determined by amino acids which flank its native location within simian virus 40 T antigen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474076      PMCID: PMC189576     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  86 in total

Review 1.  Dominance and crypticity of T cell antigenic determinants.

Authors:  E E Sercarz; P V Lehmann; A Ametani; G Benichou; A Miller; K Moudgil
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 2.  The biochemistry and cell biology of antigen processing and presentation.

Authors:  R N Germain; D H Margulies
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 3.  Peptides naturally presented by MHC class I molecules.

Authors:  H G Rammensee; K Falk; O Rötzschke
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

4.  Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations.

Authors:  T D Kierstead; M J Tevethia
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

5.  Regulation of MHC class I transport by the molecular chaperone, calnexin (p88, IP90).

Authors:  M R Jackson; M F Cohen-Doyle; P A Peterson; D B Williams
Journal:  Science       Date:  1994-01-21       Impact factor: 47.728

6.  Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes.

Authors:  T M Fu; R H Bonneau; M J Tevethia; S S Tevethia
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

7.  The three-dimensional structure of H-2Db at 2.4 A resolution: implications for antigen-determinant selection.

Authors:  A C Young; W Zhang; J C Sacchettini; S G Nathenson
Journal:  Cell       Date:  1994-01-14       Impact factor: 41.582

8.  Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter.

Authors:  J J Neefjes; F Momburg; G J Hämmerling
Journal:  Science       Date:  1993-08-06       Impact factor: 47.728

9.  Presentation of numerous viral peptides to mouse major histocompatibility complex (MHC) class I-restricted T lymphocytes is mediated by the human MHC-encoded transporter or by a hybrid mouse-human transporter.

Authors:  J W Yewdell; F Esquivel; D Arnold; T Spies; L C Eisenlohr; J R Bennink
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

10.  Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator.

Authors:  T N Schumacher; D V Kantesaria; M T Heemels; P G Ashton-Rickardt; J C Shepherd; K Fruh; Y Yang; P A Peterson; S Tonegawa; H L Ploegh
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  26 in total

1.  Protective cytotoxic T lymphocyte responses induced by DNA immunization against immunodominant and subdominant epitopes of Listeria monocytogenes are noncompetitive.

Authors:  T Yamada; H Uchiyama; T Nagata; M Uchijima; T Suda; K Chida; H Nakamura; Y Koide
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

Review 2.  Immune recognition, response, and regulation: how T lymphocytes do it.

Authors:  S Joyce
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Hierarchy, tolerance, and dominance in the antitumor T-cell response.

Authors:  N P Restifo
Journal:  J Immunother       Date:  2001 May-Jun       Impact factor: 4.456

4.  Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Authors:  Lawrence M Mylin; Todd D Schell; Melanie Epler; Caroline Kusuma; David Assis; Chelsea Matsko; Alexandra Smith; April Allebach; Satvir S Tevethia
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

5.  Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease.

Authors:  Sanda Remakus; Daniel Rubio; Xueying Ma; Alessandro Sette; Luis J Sigal
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

6.  Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.

Authors:  Mohamed S Arredouani; Stephanie S Tseng-Rogenski; Brent K Hollenbeck; June Escara-Wilke; Karen R Leander; Deborah Defeo-Jones; Clara Hwang; Martin G Sanda
Journal:  Prostate       Date:  2010-06-15       Impact factor: 4.104

7.  Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.

Authors:  T D Schell; L M Mylin; I Georgoff; A K Teresky; A J Levine; S S Tevethia
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Chunqing Luo; Ron Shapiro; Diana Metes; Geetha Chalasani; Parmjeet S Randhawa
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

9.  Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors.

Authors:  Jodi L Yorty; Satvir S Tevethia; Todd D Schell
Journal:  Cancer Immunol Immunother       Date:  2007-11-15       Impact factor: 6.968

10.  A safety-modified SV40 Tag developed for human cancer immunotherapy.

Authors:  Stephanie S Tseng-Rogenski; Mohamed S Arredouani; June F Escara-Wilke; Yilin C Neeley; Michael J Imperiale; Martin G Sanda
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.